IP and IP analogs dosage regimens for treatment of ectopic calcifications
Summary
The USPTO granted patent US12594290B2 to Sanifit Therapeutics S.A. on April 7, 2026, covering compositions and dosage regimens of inositol phosphate compounds for treating ectopic calcifications, particularly calciphylaxis. The patent specifically claims daily doses of 6-9 mg/kg of myo-inositol hexaphosphate administered three times weekly for 1-8 months.
What changed
The USPTO granted Sanifit Therapeutics a new patent covering formulations and dosing protocols for inositol phosphate-based treatments of calciphylaxis and related calcification conditions. The patent provides Sanifit with exclusive market rights for these therapeutic applications in the US through the expiration date. Competitors developing similar ectopic calcification treatments must navigate around this patent protection or pursue licensing arrangements with Sanifit.
What to do next
- Monitor for patent portfolio implications
- Review licensing opportunities
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IP and IP analogs dosage regimens for the treatment of ectopic calcifications
Grant US12594290B2 Kind: B2 Apr 07, 2026
Assignee
SANIFIT THERAPEUTICS S.A.
Inventors
Joan Perello Bestard, Carolina Salcedo Roca, Ana-Zeralda Canals Hamann
Abstract
The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.
CPC Classifications
A61K 31/7024 A61K 31/6615 A61K 31/7032 A61K 31/661 A61P 9/00 A61P 17/02 A61P 19/08
Filing Date
2025-02-27
Application No.
19065860
Claims
21
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.